Prot#MGL-3196-18: A 52-Week, Phase 3 Open-Label Extension Study, with a Single-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTR

  • Flamm, Steven L (PD/PI)
  • Rinella, Mary Eugenia (PD/PI)

Project: Research project

Project Details

Effective start/end date2/16/222/16/25


  • Pharmaceutical Research Associates, Inc. (Prot#MGL-3196-18)
  • Synta Pharmaceuticals Corp. (Prot#MGL-3196-18)